In July 2008, the FDA charged Ranbaxy with forging and concealing documents relating to an investigation into the quality of the company's drugs sold in the United States. In addition, the agency filed a motion in the district court of Maryland asking for documents from Ranbaxy. The criminal case is continuing, Throckmorton said.
Ranbaxy is one of the largest suppliers of generic drugs to the United States and has worldwide sales of $1.61 billion, 25 percent -- or $386 million worth -- of which are to the U.S.
For more about drugs on the import alert, visit the U.S. Food and Drug Administration.
SOURCES: Sept. 16, 2008, teleconference with: Douglas Throckmorton, M.D., deputy director, Center for Drug Evaluation and Research; Deborah M. Autor, director, Office of Compliance, Center for Drug Evaluation and Research, both with the U.S Food and Drug Administration